Evolution Inspired Medicine

Scenic Biotech is applying a novel approach to target discovery by harnessing genetic suppressors. Powered by our proprietary technology, Scenic scientists are obtaining a unique and more comprehensive understanding of disease biology. These insights enable us to rapidly identify and validate novel drug targets and then focus on the development of medicines with the greatest potential to impact the lives of patients.

Scenic Biotech is a spinout of the Netherlands Cancer Institute and Oxford University, and is financially backed by BioGeneration Ventures, Inkef Capital, and Oxford Sciences Innovation. Scenic Biotech has initiated a pipeline of preclinical discovery programs and was founded in 2017.

Amsterdam – Thijn Brummelkamp van scenic biotech.

Thijn Brummelkamp

Managing Director, Founder

Thijn received his PhD from the Netherlands Cancer Institute (cum laude) and was appointed as a Fellow in 2004 at the Whitehead Institute for Biomedical Research in Cambridge in the United States. He was listed among the world’s top innovators under the age of 35 by M.I.T.’s Technology Review Magazine (2005) and was awarded the prestigious EMBO Gold Medal (2013). Thijn currently is a group leader at The Netherlands Cancer Institute, Professor of Experimental Genetics at Utrecht University and Adjunct PI at the Research Center for Molecular Medicine (CeMM) in Vienna. Thijn is also a co-founder of Haplogen GmbH and a member of their Scientific Advisory Board.

Amsterdam – Sebastian Nijman en Thijn Brummelkamp van scenic biotech.

Sebastian Nijman

Managing Director, Founder

Sebastian obtained his PhD from The Netherlands Cancer Institute and was a postdoctoral fellow at the Broad Institute of Harvard and the M.I.T.. He was group leader at the Research Center for Molecular Medicine in Vienna from 2007-2014 and is a member of the Young Academy of the Austrian Academy of Sciences. In 2010 he co-founded Haplogen GmbH and was its COO until 2014. At Haplogen, he initiated a partnership with Horizon Discovery, and co-led the subsequent $12Mio acquisition of Haplogen Genomics.
Sebastian currently maintains an Adjunct Group leader and Associate Professor position at the Ludwig Institute for Cancer Research at Oxford University.

thr20180411-0003-2zw

Edward van Wezel

Board of Directors, interim chairman

Edward is Founder and Managing Partner at BioGeneration Ventures (BGV) a venture capital firm focused on building new life sciences ventures in Europe. He currently serves on several supervisory boards and was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca).

Amsterdam – Scenic Biotech

Alexandra Glucksmann

Board of Directors

Alexandra holds a Ph.D. with honors from the University of Chicago and was a post-doctoral fellow at the M.I.T.. She spent 13 years at Millennium Pharmaceuticals, ultimately serving as Vice President. She was Senior VP at Cerulean Pharma. Most recently, Alexandra served as founding chief operating officer of Editas Medicine Inc.. Alexandra is currently entrepreneur-in-residence at Third Rock Ventures and serves on the board of Women in the Enterprise of Science and Technology (WEST).

thr20180411-0001-2zw

Lucas de Breed

Board of Directors

Lucas de Breed is currently Director at Inkef Capital, where he joined in 2013. He brings over a decade of international experience in all phases of drug development, from pre-clinical stage start-ups to brand strategy and life cycle management for Top 10 Large Pharma. In his previous role at Deallus Consulting, he was responsible for their global oncology business and founded/managed the firm’s New York City office. In addition to Scenic Biotech, Lucas currently serves on the Board of Directors for NMD Pharma, TM3 Therapeutics and InteRNA Technologies. Lucas holds a Ph.D. from University College London for research conducted at the LRI (now Francis Crick Institute), and an MBA from Stanford University. He has also co-authored several scientific papers.

Andrew Mclean

Andrew McLean

Board of Directors, observer

Andy is the Life Sciences Head at Oxford Science and Innovation (OSI). Andy joined OSI from McKinsey & Co. At McKinsey he was deeply embedded in both the private equity and pharmaceuticals practices. He is a physician with training in orthopaedic surgery who also completed a degree in philosophy, politics and economics at Christ Church, Oxford.

stephen-friend

Stephen Friend

Scientific Advisory Board

Stephen is Chairman of Sage Bionetworks, President and co-founder of 4YouandMe, former Director at Apple Inc., Senior VP at Merck & Co, and co-founder of Rosetta Inpharmatics. Dr Friend has held faculty positions at Harvard Medical School, Massachusetts General Hospital, The University of Washington, and Mt Sinai Hospital. Stephen is a world leader in genetics oncology and health informatics.

Chas Bountra

Chas Bountra

Scientific Advisory Board

Chas is Chief Scientist of the Structural Genomics Consortium, Professor at the Univ. of Oxford and Imperial College London. He is the former VP and Head of Biology at GSK. At GSK he was involved in the development of over 40 clinical candidates and the launch of alosetron. Dr Bountra is on the SAB of Carrick Tx, Spinifex Pharma, Axol Bioscience, Tekcapital and IP Asset Ventures. Chas is a world leader in drug discovery and development.

Ton Schumacher

Ton Schumacher

Scientific Advisory Board

Ton is a Group leader at the Netherlands Cancer Institute and Professor of Immunotechnology at Leiden University. Dr Schumacher is Co-founder of The T-Cell Factory (acquired by Kite Pharma/Gilead), AIMM Therapeutics, and Neon Therapeutics. Ton is a world leader in tumor neoantigens and immuno-oncology.